Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Maruishi Pharmaceutical","sponsor":"CARA Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cara Therapeutics Announces Approval of KORSUVA\u00ae IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Peptide","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Maruishi Pharmaceutical","sponsor":"Allay Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Allay Therapeutics Announces Development and Commercialization Agreement with Maruishi Pharmaceutical for Ultra-Sustained Pain Therapeutics in Japan","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Maruishi Pharmaceutical

    Menu

    Maruishi Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Maruishi Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Allay Therapeutics Announces Development and Commercialization Agreement with Maruishi Pharmaceutical for Ultra-Sustained Pain Therapeutics in Japan

              Details:

              Under the agreement, Maruishi will have the exclusive rights to develop and commercialize Allay’s lead investigational drug candidate, ATX101, a non-opioid, bupivacaine-based drug product, and other ultra-sustained analgesic implantable drug candidates for acute pain in Japan.

              Lead Product(s): Bupivacaine

              Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ATX-101

              Highest Development Status: Phase II Product Type: Small molecule

              Recipient: Allay Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement December 18, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Maruishi Pharmaceutical

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients

              Details:

              Korsuva (difelikefalin) injection is a kappa opioid receptor agonist indicated for the treatment of moderate-to-severe pruritus in hemodialysis patients.

              Lead Product(s): Difelikefalin

              Therapeutic Area: Dermatology Product Name: Korsuva

              Highest Development Status: Approved Product Type: Peptide

              Recipient: CARA Therapeutics

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 25, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY